Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.02 (market cap $12.58B), while Nuvation Bio Inc. Class A Common Stock trades at $5.01 (market cap $1.74B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 7.2× Nuvation Bio Inc. Class A Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| HALO | NUVB | |
|---|---|---|
Market Cap | $12.58B | $1.74B |
Volume | 2,179,278 | 9,289,619 |
Sector | Health | Health |
52-Week High | $115.22 | $9.54 |
52-Week Low | $61.63 | $3.41 |
Typical Hold Time | 1 Days | 1 Days |
Enterprise Value | $14.49B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
